{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T07:09:26Z","timestamp":1779088166308,"version":"3.51.4"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,3,23]],"date-time":"2027-03-23T00:00:00Z","timestamp":1805760000000},"content-version":"am","delay-in-days":265,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["T32 DA007294"],"award-info":[{"award-number":["T32 DA007294"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Schizophrenia Research"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.schres.2026.03.015","type":"journal-article","created":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T14:24:21Z","timestamp":1774275861000},"page":"1-7","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Aripiprazole two-month long-acting injectable may increase time to readmission compared to aripiprazole one-month in patients with schizophrenia and schizoaffective disorder"],"prefix":"10.1016","volume":"293","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9092-8491","authenticated-orcid":false,"given":"Sean T.","family":"Lynch","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathryn Brooke","family":"Renard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angelo I.","family":"Chaia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa J.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carisa M.","family":"Kymissis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.schres.2026.03.015_bb0005","doi-asserted-by":"crossref","DOI":"10.1186\/1471-244X-10-2","article-title":"The cost of relapse and the predictors of relapse in the treatment of schizophrenia","volume":"10","author":"Ascher-Svanum","year":"2010","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.schres.2026.03.015_bb0010","article-title":"Predictors of relapse and functioning in first-episode psychosis: a two-year follow-up study","author":"Berg\u00e9","year":"2015","journal-title":"Psychiatr. Serv."},{"key":"10.1016\/j.schres.2026.03.015_bb0015","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1080\/03007995.2017.1410471","article-title":"Efficacy and safety of aripiprazole lauroxil once-monthly versus aripiprazole once-monthly long-acting injectable formulations in patients with acute symptoms of schizophrenia: an indirect comparison of two double-blind placebo-controlled studies","volume":"34","author":"Cameron","year":"2018","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.schres.2026.03.015_bb0020","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1586\/17512433.2016.1121809","article-title":"Aripiprazole long-acting injectable formulations for schizophrenia: aripiprazole monohydrate and aripiprazole lauroxil","volume":"9","author":"Citrome","year":"2016","journal-title":"Expert. Rev. Clin. Pharmacol."},{"key":"10.1016\/j.schres.2026.03.015_bb0025","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.23m14873","article-title":"Safety and efficacy of aripiprazole 2-month ready-to-use 960 mg: secondary analysis of outcomes in adult patients with schizophrenia in a randomized, open-label, parallel-arm, pivotal study","volume":"84","author":"Citrome","year":"2023","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.schres.2026.03.015_bb0030","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1016\/j.clinthera.2018.07.011","article-title":"Health care resource utilization and costs associated with transitioning to 3-month Paliperidone palmitate among US veterans","volume":"40","author":"DerSarkissian","year":"2018","journal-title":"Clin. Ther."},{"key":"10.1016\/j.schres.2026.03.015_bb0035","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1093\/oxfordjournals.schbul.a033316","article-title":"Predictors of relapse and Rehospitalization in schizophrenia and schizoaffective disorder","volume":"24","author":"Doering","year":"1998","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2026.03.015_bb0040","doi-asserted-by":"crossref","first-page":"4530","DOI":"10.3390\/jcm11154530","article-title":"Second-generation antipsychotics\u2019 effectiveness and tolerability: a review of real-world studies in patients with schizophrenia and related disorders","volume":"11","author":"Fabrazzo","year":"2022","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.schres.2026.03.015_bb0045","first-page":"S128","article-title":"Hospitalization readmission rates in patients with schizophrenia: a nationwide analysis","volume":"66","author":"Gon\u00e7alves Pinho","year":"2023","journal-title":"Eur. Psychiatry"},{"key":"10.1016\/j.schres.2026.03.015_bb0050","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.jpsychires.2022.12.044","article-title":"Clinical determinants, patterns and outcomes of antipsychotic medication prescribing in the treatment of schizophrenia and schizoaffective disorder: a naturalistic cohort study","volume":"158","author":"Groenendaal","year":"2023","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.schres.2026.03.015_bb0055","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1177\/2045125318781475","article-title":"The acute efficacy of antipsychotics in schizophrenia: a review of recent meta-analyses","volume":"8","author":"Haddad","year":"2018","journal-title":"Ther. Adv. Psychopharmacol."},{"key":"10.1016\/j.schres.2026.03.015_bb0060","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s40263-023-00996-8","article-title":"A randomized, open-label, multiple-dose, parallel-arm, pivotal study to evaluate the safety, tolerability, and pharmacokinetics of aripiprazole 2-month long-acting injectable in adults with schizophrenia or bipolar I disorder","volume":"37","author":"Harlin","year":"2023","journal-title":"CNS Drugs"},{"key":"10.1016\/j.schres.2026.03.015_bb0065","doi-asserted-by":"crossref","first-page":"215","DOI":"10.3325\/cmj.2008.2.215","article-title":"Two-year Rehospitalization rates of patients with newly diagnosed or chronic schizophrenia on atypical or typical antipsychotic drugs: retrospective cohort study","volume":"49","author":"Herceg","year":"2008","journal-title":"Croat. Med. J."},{"key":"10.1016\/j.schres.2026.03.015_bb0070","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1007\/s00127-018-1650-7","article-title":"Five-year rehospitalization experience of a state-wide cohort of persons with schizophrenia","volume":"54","author":"Hudson","year":"2019","journal-title":"Soc. Psychiatry Psychiatr. Epidemiol."},{"key":"10.1016\/j.schres.2026.03.015_bb0075","unstructured":"IBM SPSS Statistics for Windows, 2021."},{"key":"10.1016\/j.schres.2026.03.015_bb0080","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1017\/S1092852919000816","article-title":"Size matters: the importance of particle size in a newly developed injectable formulation for the treatment of schizophrenia","volume":"25","author":"Jain","year":"2020","journal-title":"CNS Spectr."},{"key":"10.1016\/j.schres.2026.03.015_bb0085","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1080\/03007995.2017.1359516","article-title":"Baseline characteristics and treatment patterns of patients with schizophrenia initiated on once-every-three-months paliperidone palmitate in a real-world setting","volume":"33","author":"Joshi","year":"2017","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.schres.2026.03.015_bb0090","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.4088\/JCP.v68n1106","article-title":"A comparison of selected risk factors for unipolar depressive disorder, bipolar affective disorder, schizoaffective disorder, and schizophrenia from a danish population-based cohort","volume":"68","author":"Laursen","year":"2007","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.schres.2026.03.015_bb0095","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1080\/03007995.2021.1882412","article-title":"Medication adherence, healthcare resource utilization, and costs among Medicaid beneficiaries with schizophrenia treated with once-monthly paliperidone palmitate or once-every-three-months paliperidone palmitate","volume":"37","author":"Lin","year":"2021","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.schres.2026.03.015_bb0100","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.2147\/NDT.S221242","article-title":"Comparison of relapse prevention with 3 different paliperidone formulations in patients with schizophrenia continuing versus discontinuing active antipsychotic treatment: a post-hoc analysis of 3 similarly designed randomized studies","volume":"16","author":"Mathews","year":"2020","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"10.1016\/j.schres.2026.03.015_bb0105","doi-asserted-by":"crossref","first-page":"531","DOI":"10.2147\/NDT.S395383","article-title":"The effect of longer dosing intervals for long-acting injectable antipsychotics on outcomes in schizophrenia","volume":"19","author":"Milz","year":"2023","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"10.1016\/j.schres.2026.03.015_bb0110","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0195687","article-title":"Prevalence of psychotic disorders and its association with methodological issues. A systematic review and meta-analyses","volume":"13","author":"Moreno-K\u00fcstner","year":"2018","journal-title":"PloS One"},{"key":"10.1016\/j.schres.2026.03.015_bb0115","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1093\/ijnp\/pyab071","article-title":"A randomized, double-blind, multicenter, noninferiority study comparing paliperidone palmitate 6-month versus the 3-month long-acting injectable in patients with schizophrenia","volume":"25","author":"Najarian","year":"2022","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.schres.2026.03.015_bb0120","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/s41537-020-00122-3","article-title":"Effectiveness of antipsychotic drugs in schizophrenia: a 10-year retrospective study in a Korean tertiary hospital","volume":"6","author":"Oh","year":"2020","journal-title":"NPJ Schizophr."},{"key":"10.1016\/j.schres.2026.03.015_bb0125","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1007\/s40261-019-00801-9","article-title":"Long-acting injectable (LAI) aripiprazole formulations in the treatment of schizophrenia and bipolar disorder: a systematic review","volume":"39","author":"Rapinesi","year":"2019","journal-title":"Clin. Drug Investig."},{"key":"10.1016\/j.schres.2026.03.015_bb0130","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1001\/archpsyc.56.3.241","article-title":"Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder","volume":"56","author":"Robinson","year":"1999","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.schres.2026.03.015_bb0135","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0020141","article-title":"A systematic review of the prevalence of schizophrenia","volume":"2","author":"Saha","year":"2005","journal-title":"PLoS Med."},{"key":"10.1016\/j.schres.2026.03.015_bb0140","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1080\/14737175.2024.2313550","article-title":"Evaluating the efficacy and safety of the currently available once-every-two months long-acting injectable formulations of aripiprazole for the treatment of schizophrenia or as a maintenance monotherapy for bipolar I disorder in adults","volume":"24","author":"Samalin","year":"2024","journal-title":"Expert Rev. Neurother."},{"key":"10.1016\/j.schres.2026.03.015_bb0145","doi-asserted-by":"crossref","DOI":"10.1176\/appi.ps.201100084","article-title":"Predictors of relapse in the year after hospital discharge among patients with schizophrenia","author":"Schennach","year":"2012","journal-title":"Psychiatr. Serv."},{"key":"10.1016\/j.schres.2026.03.015_bb0150","doi-asserted-by":"crossref","DOI":"10.1093\/ijnp\/pyad067","article-title":"Relapse rates with paliperidone palmitate in adult patients with schizophrenia: results for the 6-month formulation from an open-label extension study compared to real-world data for the 1-month and 3-month formulations","volume":"27","author":"Turkoz","year":"2024","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.schres.2026.03.015_bb0155","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/S2215-0366(19)30406-7","article-title":"Clinical and social factors associated with increased risk for involuntary psychiatric hospitalisation: a systematic review, meta-analysis, and narrative synthesis","volume":"6","author":"Walker","year":"2019","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.schres.2026.03.015_bb0160","doi-asserted-by":"crossref","first-page":"e813","DOI":"10.4088\/JCP.16m11308","article-title":"Does half-life matter after antipsychotic discontinuation? A relapse comparison in schizophrenia with 3 different formulations of paliperidone","volume":"78","author":"Weiden","year":"2017","journal-title":"J. Clin. Psychiatry"}],"container-title":["Schizophrenia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996426000927?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996426000927?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T06:35:40Z","timestamp":1779086140000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920996426000927"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":32,"alternative-id":["S0920996426000927"],"URL":"https:\/\/doi.org\/10.1016\/j.schres.2026.03.015","relation":{},"ISSN":["0920-9964"],"issn-type":[{"value":"0920-9964","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Aripiprazole two-month long-acting injectable may increase time to readmission compared to aripiprazole one-month in patients with schizophrenia and schizoaffective disorder","name":"articletitle","label":"Article Title"},{"value":"Schizophrenia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.schres.2026.03.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}